All In Biotech

Drug Trial Radar · NCT07545590

A Study of Eltrekibart (LY3041658) in Healthy Participants

A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Apr 21, 2026

Primary completion

Sep 22, 2026

Study completion Sep 22, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.

Conditions

  • Healthy

Interventions

  • LY3041658Drug

    Administered SC

  • LY3041658Drug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658Time frame: Predose on Day 1 up to Day 85
  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3041658Time frame: Predose on Day 1 up to Day 85
  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration AUC(0-tlast) of LY3041658Time frame: Predose on Day 1 up to Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.